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Abstract
Background: The treatment strategy usually depends on the disease state in the individual patient.
However, it is difficult to estimate the disease state before treatment in many patients. The purpose
of this study was to develop a BAC (bacterial artificial chromosome) mini-array allowing for the
estimation of node metastasis, liver metastasis, peritoneal dissemination and the depth of tumor
invasion in gastric cancers.
Methods: Initially, the DNA copy number aberrations (DCNAs) were analyzed by array-based
comparative genomic hybridization (aCGH) in 83 gastric adenocarcinomas as a training-sample set.
Next, two independent analytical methods were applied to the aCGH data to identify the BAC
clones with DNA copy number aberrations that were linked with the disease states. One of the
methods, a decision-tree model classifier, identified 6, 4, 4, 4, and 7 clones for estimating lymph
node metastasis, liver metastasis, peritoneal dissemination, depth of tumor invasion, and
histological type, respectively. In the other method, a clone-by-clone comparison of the frequency
of the DNA copy number aberrations selected 26 clones to estimate the disease states.
Results: By spotting these 50 clones together with 26 frequently or rarely involved clones and 62
reference clones, a mini-array was made to estimate the above parameters, and the diagnostic
performance of the mini-array was evaluated for an independent set of 30 gastric cancers (blinded
– sample set). In comparison to the clinicopathological features, the overall accuracy was 66.7% for
node metastasis, 86.7% for liver metastasis, 86.7% for peritoneal dissemination, and 96.7% for
depth of tumor invasion. The intratumoral heterogeneity barely affected the diagnostic
performance of the mini-array.
Conclusion: These results suggest that the mini-array makes it possible to determine an optimal
treatment for each of the patients with gastric adenocarcinoma.
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Background
Gastric adenocarcinoma is one of the most frequent can-
cers worldwide, and it is the second leading cause of can-
cer death [1]. Although new diagnostic and therapeutic
procedures are being developed, many patients still never-
theless die of the disease. The improvement of prognosis
by the most optimal treatment is the first priority for all
cancer patients. It is true that detection is critical to a rapid
cure, though under the present circumstances gastric can-
cers are detected at various stages. The treatment strategy
usually depends on the disease state in each individual
patient. Surgery with a curative intent is applied to
advanced cancers, while an endoscopic mucosal resection
(EMR) or endoscopic submucosal dissection (ESD) is
applied to early cancer without lymph node metastasis
[2]. Accordingly, it is necessary to elucidate the disease
state of an individual patient before any treatment or ther-
apeutic procedure is started. In particular, an accurate
evaluation of the nodal status and disease stage is critical
in order to determine the appropriate treatment. How-
ever, the assessment of the disease state before treatment
is not easy by conventional tests such as endoscopic
inspection and microscopic examination of biopsy speci-
mens. It is generally accepted that the biological character-
istics of cancer are primarily dependent on the underlying
genetic alterations of cancer cells. Therefore, a compre-
hensive analysis of the genomic changes in an individual
type of cancer is necessary for identifying the genomic
changes linked with the clinicopathological features.
Microarray technology accomplishes this purpose. Array-
based comparative genomic hybridization (aCGH), a spe-
cific microarray method, allows the locus-by-locus meas-
urement of DNA copy number aberrations (DCNAs) in
cancer cells with a high resolution [3]. The aCGH has been
applied to surgically removed gastric cancers to identify
the chromosomal regions associated with carcinogenesis
[4-9]. However, information concerning the relationship
between DCNAs and the disease state is currently very
limited. The identification of BAC clones with DCNAs
that are linked with disease states may allow the exact esti-
mation of disease states even in biopsy specimens at the
time of the histological diagnosis, or before treatment.
When a mini-array as a gastric cancer classifier that makes
possible the quantitative measurement of genomic altera-
tions is developed, it will be possible to estimate the dis-
ease state of each tumor for optimal treatment. The mini-
array CGH may provide information concerning the dis-
ease states in order to determine the optimal treatment in
individual cancer patients, thus contributing to personal-
ized gastric cancer care.
In this study, the statistical analyses of aCGH data
obtained from 83 sporadic gastric cancers identified 50
BAC clones linked with disease states including node
metastasis, liver metastasis, peritoneal dissemination, the
depth of tumor invasion and the histological type in gas-
tric cancers. Next, using these BAC clones, a mini-array
was constructed to evaluate the disease states of gastric
cancer. In addition, the diagnostic performance of the
mini-array was evaluated for an independent set of 30 gas-
tric cancers. This is the first report of the development of a
BAC mini-array which thus makes it possible to estimate
the disease state in gastric cancer.
Methods
Tissue specimens and DNA samples
Eighty-three consecutive surgically removed gastric aden-
ocarcinomas were evaluated for the selection of BAC
clones linked with the clinicopathological features. They
included 10 early cancers and 73 advanced cancers. The
patients consisted of 62 males and 21 females with an
average age of 70 years ranging from 44 to 89 years old.
The family histories were noncontributory for all patients
and all tumors were considered to be sporadic. The clin-
icopathological features are summarized in Table 1. In
brief, according to Lauren's histological classification, 41
tumors were classified as intestinal-type gastric cancer,
while the others were diffuse-type cancers. Node and liver
metastases were detected in 60 and 6 cancers, respectively.
In this series, 19 tumors showed a peritoneal dissemina-
tion of the cancer cells. The tissue specimens were stored
at -80°C until use. A tissue microdissection technique was
used to reduce the contamination of the normal tissue
components for the array CGH analyses, as previously
described [10]. High molecular weight genomic DNA was
extracted from the microdissected tumor tissue specimens
with a DNA extraction kit (SepaGene, Sankojunyaku Co.,
Ltd, Tokyo, Japan) according to the manufacturer's
instructions [11-13]. Control DNA (Promega, Madison,
WI) was used as a reference. The study protocol was con-
ducted under the approval of the Institutional Review
Board for Human Use at the Yamaguchi University School
of Medicine in 2004, and informed consent for this study
was obtained from every patient.
Array CGH for screening
The array CGH experiments were performed with a
MacArray™ Karyo 1400 (Macrogen Inc., Seoul, Korea)
according to the manufacturer's protocol http://
www.macrogen.co.kr/eng/biochip/karyo_summary.jsp,
which provided the BAC chip information together with
information of the end-sequenced BAC clones and data
processing methods, as previously described [14-16]. The
arrays consisted of triplicate spotted 1,440 human bacte-
rial artificial chromosome (BAC) clones, including 356
cancer-related genes, which covered the whole human
genome at an average interval of 2.3 Mb. Sample and gen-
der matched reference genomic DNAs (500 ng each) were
labeled by the random priming method with fluorescence
dyes, Cy 3 and Cy 5, respectively. The labeled DNAs wereBMC Cancer 2008, 8:393 http://www.biomedcentral.com/1471-2407/8/393
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mixed with Cot-1 DNA (50 μg, Gibco BRL, Gaithersburg,
MD) and then were hybridized to the array slides for 2
days at 37°C in a moist chamber. The array slides were
rinsed in a washing buffer and dried well. The array slides
were scanned with a Gene Pix 4000A scanner (Axon
Instruments, Union City, CA). The fluorescence images
were analyzed using the MAC Viewer™ software program
(Macrogen Inc.) optimized for the analysis of the array as
previously reported [14-16]. The fluorescence spots were
defined with the automatic grid feature and adjusted man-
ually. All CGH ratios were automatically converted to log
base 2. The ratios of the fluorescence intensities of all
spots were plotted against the distance of the clones along
the chromosomes. For each BAC clone, the average ratios
that deviated significantly from zero were considered to
be abnormal (± log2 0.25), and almost all spots were
within the area between the cutoff lines (± log2 0.25) for
male/female DNA samples. In addition, we defined log2
ratio >1.0 as amplifications.
Array CGH data analysis
The aCGH data of the 83 gastric cancers were analyzed by
two independent methods referred to as method 1 and
method 2 for convenience. In method 1, a WEKA deci-
sion-tree model classifier, J48 http://
www.cs.waikato.ac.nz/ml/weka/[17] was applied to the
aCGH data to identify the BAC clones and their copy
numbers for differentiating between gastric cancers with
and without node metastasis, with and without liver
metastasis, with and without peritoneal dissemination,
between early and advanced cancers, and between intesti-
nal type and diffuse type cancers. In method 2, the clone-
by-clone frequency of the DCNAs between the two
groups,  e.g., between cancer with and without node
metastasis, was compared using the χ2-test to identify the
BAC clones that were used for the distinction between two
groups. The difference was considered significant when its
P-value was less than 0.05, and the BAC clones with a P-
value of less than 0.01 were used for the fabrication of a
mini-array specific for gastric cancer.
Customization of BAC mini-array specific for gastric 
cancer
The mini-array was made using 50 BAC clones chosen by
the two analytical methods of the aCGH data from 83 gas-
tric cancers to estimate node and liver metastases, perito-
neal dissemination, depth of tumor invasion, and
histological type; the method 1 identified 24 BAC clones
of which one was shared between node metastasis and
liver metastasis, and the method 2 identified 26 clones. In
addition to these BAC clones, the mini-array also con-
tained 26 clones with frequent or infrequent DCNAs and
62 reference clones. A total of 138 BAC clones were spot-
ted in triplicate on two discrete parts of a glass slide, and
therefore, each slide was used for two specimens (Fig 1b).
Table 1: Clinicopathological summary of 83 gastric adenocarcinomas
For Screening
The number of gastric cancers examined: 83
Average age of patients (range): 70 years old (44 – 89 years)
Histological type of gastric cancers
Intestinal-type: 41
Diffuse-type: 42
Intestinal-type Diffuse-type
Average age (years) 72 68
Sex (F/M) 9/32 12/30
Node metastasis 26 34
Liver metastasis 3 3
Peritoneal dissemination 7 12
Early/advanced cancers* 6/35 4/38
For validation of the mini-array
The number of gastric cancers examined: 30
Average age of patients (range): 69.3 years old (44 – 88 years)
Sex (F/M) 11/19
Histological type of gastric cancers
Intestinal/diffuse 13/17
Node metastasis 9
Liver metastasis 3
Peritoneal dissemination 5
Early/advanced cancers* 3/27
*Early gastric cancer is defined as a tumor with invasion limited to mucosa or submucosa according to the Japanese classification of gastric 
carcinoma (9).BMC Cancer 2008, 8:393 http://www.biomedcentral.com/1471-2407/8/393
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Validation of performance for mini-array
The performance of the mini-array was evaluated for node
metastasis, liver metastasis, peritoneal dissemination,
depth of invasion, and histological type of gastric cancers
for an independent set of 30 gastric cancers (Table 1). The
cutoff value was also applied to data analysis of the mini-
array. The copy numbers for 138 BAC clones were com-
pared between the screening arrays and the mini-arrays.
When the diagnosis was different between the two meth-
ods, priority was given to the diagnosis that indicated a
more advanced stage in the evaluation of the mini-array.
Effects of intratumoral heterogeneity on the performance 
of mini-array
The effects of the intratumoral genomic heterogeneity on
the performance of the mini-array in the randomly
selected five gastric tumors were examined. Four tissue
specimens were taken from different parts of a tumor. The
procedures for tissue microdissection, DNA extraction,
aCGH and the data analysis were as noted above.
Results
The DCNAs were detected by aCGH for the multiple BAC
clones in all gastric adenocarcinomas. Although the
number of BAC clones with DCNA varied from tumor to
tumor, roughly 15% of clones showed DCNAs for each
tumor. Overall, frequent DNA copy number gains were
detected for chromosomal regions 20q12-q13 (at the fre-
quency of 43%), and 8q24 (43%), and frequent DNA
copy number losses were detected for chromosomal
regions 4q35.2 (37%), 1p36 (36%), 4q34 (36%), 4q12
(35%), 14q32 (33%), and 22q11 (34%), in addition to
the Y chromosome (Fig 1a and see Additional file 1).
The comparison of the aCGH data with the clinicopatho-
logical features of the tumors using the decision-tree clas-
sifier (method 1) allowed the identification of the BAC
clones for the differentiation between gastric cancers with
and without specific clinicopathological characters. The
gastric cancers with node metastasis were distinguished
from those without it with an accuracy of 100% by exam-
ining the extent of the DCNAs for the six BAC clones
mapped to 5q13.2, 13q31.1, 1p22.3, 1p34.2, 14q32.2,
and 3q13.12 (Fig 2a). The procedures of the analysis were
as follows: The DNA copy number of a tumor at 5q13.2
was applied to the criterion of the first clone. If the DNA
copy number of the clone was % -0.349, the tumor was
classified as a tumor without node metastasis. Six of 83
tumors were classified into this group. When the DNA
copy number of the tumor was not the case at the first
clone, the second criterion (>-0.37) was checked. Five
tumors were separated from the remaining 77 tumors.
When the DNA copy number of the clone at 13q31.1 was
% 0.37 in the tumor, then the third clone located on
1p22.3 was examined. If the DNA copy number of the
tumor met the criterion of the third clone, % -0.042,
nodal metastasis was considered positive in this tumor.
Thirty-six cancers were classified into this category. In this
way, the DNA copy number of the tumor was in turn
examined from the first to the sixth clone. Eventually, all
gastric cancers were classified into either of the two
groups, cancers with and without node metastasis.
Gastric adenocarcinomas with liver metastasis were sepa-
rated from those without it at a 100% accuracy rate by
checking the DNA copy number for the four BAC clones
mapped to 1q44-qter, 5q13.2, 6q23.2, and 7q31.1, as
shown in Fig 2b. The high level loss of 5q13.2 was
detected in tumors with neither node nor liver metastasis.
The decision-tree classifier also permitted the classifica-
tion of gastric cancer into either a tumor with or without
peritoneal dissemination at the correct classification rate
of 98.8% by the copy number alterations of the four BAC
clones mapped to 4q13.3, 4q32.2, 13q12.13, and
12q24.23 (Fig 2c). The decision-tree classifier made it pos-
sible to divide the gastric cancers into two groups, early
and advanced cancers, on the basis of the DNA copy
number of the four BAC clones mapped to 1q43, 21q22.2,
16q22.1, and 6p21.1 (Fig 2d). In addition, the examina-
tion of the seven BAC clones made it possible to accu-
rately differentiate between these two histologic types, the
intestinal-type and the diffuse-type (Fig 2e). A DNA copy
number change in a clone located in 5q13.2 was linked
with both node and liver metastasis, and in total 24 clones
were identified by method 1.
A statistical analysis of the aCGH data was also performed
using the protocol referred to as method 2 to identify the
clones for classifying the gastric cancers into two groups
with opposite characteristics. The comparison of the fre-
quency of the DCNAs clone-by-clone revealed many BAC
clones with statistical differences in their frequency
between the tumors with and without node metastasis,
between the tumors with and without liver metastasis,
between the tumors with and without peritoneal dissem-
ination, and between the intestinal- and diffuse-type can-
cers. Seven, six, five, and eight BAC clones, for a total of 26
clones, were selected to evaluate for node metastasis, liver
metastasis, peritoneal dissemination, and histological
type, respectively (Table 2).
DNA amplification was detected at chromosomal regions
17q21.1(harboring HER-2), 11q13.3 (CCND1), and
11q13 (FGF4) in four, three, and three tumors, respec-
tively, though the amplification was not correlated with
any clinicopathological feature of the gastric cancers.
Validation of the mini-array
The dye-swap hybridization experiments revealed that the
switching of the dyes did not affect the aCGH profiles (FigBMC Cancer 2008, 8:393 http://www.biomedcentral.com/1471-2407/8/393
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(a) Frequency of gains and losses in 83 gastric cancers Figure 1
(a) Frequency of gains and losses in 83 gastric cancers. A green line denotes a copy number gain and a red line denotes 
a copy number loss. Gains of 7p, 8q, and 20q, and losses of 4q, 17p, and 21 are frequent in gastric adenocarcinoma. (b-left) 
Design of a mini-array. The mini-array spotted with 50 BAC clones chosen by two analytical methods of the aCGH data from 
83 gastric cancers to estimate the node and liver metastases, peritoneal dissemination, depth of tumor invasion, and histologi-
cal type, 26 clones with frequent or infrequent DCNAs, and 62 reference clones. A total of 138 BAC clones were spotted in 
triplicate on two discrete parts of a glass slide, and therefore, each slide was used for two specimens. The diameter of each 
spot is approximately 200 μm. (b-right) A hybridization image for the mini-array. Note the same color image for three spots 
each in the mini-array. (c) A comparison of aCGH profiles between the screening chip (upper) and the mini-array (lower) for a 
case of gastric adenocarcinoma. A profile of aCGH in the mini-array basically replicates that in the screening array. The red 
lines indicate log2 0.25 and -log2 0.25, respectively. The green and red spots indicate the BAC clones with a copy number gain 
and loss, respectively.BMC Cancer 2008, 8:393 http://www.biomedcentral.com/1471-2407/8/393
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3). The diagnostic performance of the mini-array was eval-
uated for the independent set of 30 gastric cancers.
Although the density of the dots was less in the mini-array
than in the screening 1.4 K arrays, the data by the mini-
array analysis were virtually equivalent to those by the
screening array (Fig 1c). The copy number of each clone in
the mini-array correlated well with that of the correspond-
ing clone in the screening array (average correlation coef-
ficient r = 0.747, ranging from 0.664 to 0.920). First, the
mini-array data analysis was made regardless of the clin-
icopathological features, and then, the aCGH data from
the mini-array were checked out against the clinicopatho-
logical features of an individual tumor. The diagnostic
accuracy was considerably high even in a single analysis
method and was not significantly different between the
two methods, as shown in Table 3. However, the combi-
nation of the two analytical methods slightly improved
the accuracy for all parameters except for the histological
typing (Table 3). The overall diagnostic accuracy was as
follows: 66.7% (sensitivity; 0.95, and specificity; 0.0) for
node metastasis, 86.7% (sensitivity; 0.67 and specificity;
0.89) for liver metastasis, 86.7% (sensitivity; 0.20, and
specificity; 1.0) for peritoneal dissemination, and 96.7%
(sensitivity; 1.0, and specificity 0.67) for the depth of
tumor invasion (Table 3). Nine of ten cancers misclassi-
fied by the mini-array were false positives, and one of
them was a false negative with regard to the evaluation of
node metastasis. As for the estimation of liver metastasis,
four cancers were misclassified; three of them were false
positives and one was a false negative. As for the estima-
tion of peritoneal dissemination, all of the misclassified
cancers were false negatives (Table 3). As for the estima-
tion of the depth of tumor invasion, only a single case was
misclassified by the mini-array and it was overdiagnosed
(Table 3).
Effects of intratumoral heterogeneity on the diagnostic 
performance of the mini-array
A slight variation in the DNA copy number of the BAC
clone was observed between the samples taken from a sin-
gle tumor. Regardless of whether the samples provided a
correct diagnosis, however, the diagnosis hardly differed
between the four samples from the same tumor (Table 4).
In particular, there were no BAC clones with a copy
number variation affecting the estimation of liver metas-
tasis and peritoneal dissemination in all tumors. Occa-
sionally there were tumors in which one or two clones
affecting the diagnosis were present for one or two items
(Table 4). In one early cancer (invasion into the submu-
cosal layer), however, one of four tissue specimens cor-
rectly estimated the tumor as an early cancer, while the
others estimated it as an advanced cancer. In another case,
three of the four tissue specimens correctly estimated a
tumor as an advanced cancer, while the other estimated it
as an early cancer. However, the overall diagnostic accu-
racy (in the combination of methods 1 and 2) was virtu-
ally unaffected by the intratumoral heterogeneity.
Discussion
The evaluation of the disease state before treatment is nec-
essary to appropriately select the optimal treatments with
a high therapeutic efficiency and high quality of life for
each patient with gastric cancer. With this view, the
genomic changes characterizing gastric cancers have been
investigated [5-10,13]. The chromosomal regions with
frequent copy number aberrations in gastric cancers were
easily detected by aCGH [5,7,18,19], and some of them
were reported as a genomic marker associated with perito-
neal dissemination [20] and node metastasis of gastric
cancer [6,18,19,21]. However, the examination of only a
few genomic markers is insufficient for the precise estima-
tion of the disease state. Alternatively, the combination of
the genomic markers with a strong diagnostic impact may
allow for the precise estimation of the disease state in each
case. The present study demonstrated that the comparison
of the DNA copy number of each BAC clone between the
two groups of tumors with opposite characteristics identi-
fied the BAC clones linked with the disease states includ-
ing node metastasis, liver metastasis, peritoneal
dissemination, depth of tumor invasion, and histological
type of gastric cancer. Two independent data analysis
methods selected the BAC clones allowing for the reliable
classification of 83 gastric cancers (training samples) into
two tumor groups with opposite characteristics. In total,
50 BAC clones were selected as genomic markers for esti-
mating the disease states of the gastric cancers. With the
exception of a single clone located in 5q13.2 these clones
were associated with only a single characteristic of the dis-
ease states. The copy number loss of the clone in 5q13.2
was frequent in the gastric cancers with neither node nor
liver metastasis, but the converse was not true. Therefore,
although the genetic mechanisms are partly shared by the
lymph node and liver metastases of gastric cancer, it is
convenient to think that the genomic alterations associ-
ated with tumor metastasis are basically different between
the target organs, as explained by the well-known 'seed
and soil' theory. The BAC clones involved in tumor metas-
tasis are obviously different from the clones involved in
the peritoneal dissemination of tumors. These BAC clones
identified can be biomarkers to estimate the disease state
by definition [22]. At present, however, it is uncertain
whether the genes located in these BAC clones are truly
involved in the invasion, metastasis or dissemination of
gastric cancer, and how the genes participate in the node
metastasis, liver metastases or peritoneal dissemination of
gastric cancer.
Microarray technologies are being applied to cancer diag-
nosis and the prognostic prediction in malignancies. A
microarray-based gene expression analysis has been pro-BMC Cancer 2008, 8:393 http://www.biomedcentral.com/1471-2407/8/393
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Identification of BAC clones by a decision-tree algorithm to classify the gastric cancers into two groups with different charac- ters Figure 2
Identification of BAC clones by a decision-tree algorithm to classify the gastric cancers into two groups with 
different characters. (a) Differentiation between gastric cancers with and without node metastasis. These two groups can be 
clearly differentiated by examining the degree of the copy number changes of six BAC clones mapped to 5q13.2, 13q31.1, 
1p22.3, 1p34.2, 14q32.2, and 3q13.12 in descending order. A tumor of which the copy number at 5q13.2 was ≤ -0.346 (log2) 
shows no node metastasis. When the DNA copy number of the tumor was not the case at the first clone, the second criterion 
(>-0.37 at 13q31.1) was checked. Five tumors were separated from the remaining 77 tumors at this point. When the DNA 
copy number of the clone at 13q31.1 was % 0.37 in the tumor, the third clone located on 1p22.3 was examined. If the DNA 
copy number of the tumor meets the criterion of the third clone, % -0.042, nodal metastasis was positive in this tumor. Thirty-
six cancers were classified into this category at this point. In this way, the DNA copy number of the tumor was in turn exam-
ined from the first to the sixth clone. Each step successively sorts a cluster of either group. Eventually, all gastric cancers were 
classified into either of two groups, cancers with and without node metastasis. The figures in parentheses indicate the number 
of tumors fitting the requirements. The correctly classified instances were 83 (100%), and the incorrectly classified instances 
were 0 (0%). In this classifier, the number of leaves is seven, and the size of the tree was 13. In the same way as the case of 
node metastasis, BAC clones and their copy numbers were determined for liver metastasis (b), peritoneal dissemination (c), 
depth of tumor invasion (early or advanced cancer)(d), and histologic type (e).BMC Cancer 2008, 8:393 http://www.biomedcentral.com/1471-2407/8/393
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posed to estimate the prognosis of cancer patients [23,24],
and a small number of specific microarrays have been
developed for this purpose [22,23].
In this study, a gastric cancer specific mini-array was spot-
ted with 138 BAC clones including 50 clones chosen by
the screening of 83 cancers. The number of spots in the
Table 3: Diagnostic accuracy of the mini-array for an independent series of 30 gastric cancers
Node Metastasis Liver Metastasis Peritoneal Dissemination Advanced cancers
Accuracy
Method1 19/30 (63.3%) 27/30 (90.0%) 25/30 (83.3%) 29/30 (96.6%)
Method 2 20/30 (66.7%) 26/30 (86.7%) 26/30 (86.3%) -
Overall Accuracy 20/30 (66.7%) 26/30 (86.7%) 26/30 (86.7%) 29/30 (96.7%)
Sensitivity 20/21 (0.95) 2/3 (0.67) 1/5 (0.20) 27/27 (1.0)
Specificity 0/9 (0.0) 24/27 (0.89) 25/25 (1.0) 2/3 (0.67)
False positive 9/9 (1.0) 3/27 (0.11) 0/25 (0.0) 1 (over-diagnosis)
False negative 1/21 (0.05) 1/3 (0.33) 4/5 (0.80) 0 (under-diagnosis)
Table 2: 
BAC ID Chrom. region Candidate Gene Frequency of DCNAs(%) Frequency of DCNAs(%) P-value*
Gain
Node metastasis Positive (n = 60) Negative (n = 23)
225 2q24.32 TMEM132D 3 26 0.0005
1308 5q13.2 FCHO2, MGC13034 7 43 0.0005
491 16p13.11 PKD1P3 5 35 0.0006
884 19q13.32 N.i. 5 30 0.0006
Liver metastasis Positive (n = 6) Negative (n = 77)
1322 1p13.2 CHIA, C1orf88, OVGP1 43 3 <0.0001
1271 8p22 N.i. 67 13 0.0016
92 11p15 ST5 43 6 0.0006
Peritoneal dissemination Positive (n = 19) Negative (n = 64)
948 15q22.1 MYO1E, LDHAL6B 22 0 0.0002
155 Xp21.2 XK 35 5 0.0009
Histologic type Diffuse (n = 42) Intestinal (n = 41)
563 10p15.3 DIP2C 7 38 0.0011
911 10q24.2 SPFH1, CHUK, CWF19L1 0 23 0.0013
Loss
Node metastasis Positive (n = 60) Negative (n = 23)
936 8p21.2 DOCK5, GNRH1, KCTD9, CDCA2 3 23 0.0023
1158 8p21.1 EXTL3 3 21 0.0023
878 13q31.2 SLITRK5 13 47 0.0007
Liver metastasis Positive (n = 6) Negative (n = 77)
877 1p32.3 LRP8, 50 5 0.0006
1386 7q35 CNTNAP2, 43 4 0.0001
309 21q22.3 HSF2BP, KIAA0179, 29 1 0.0002
Peritoneal dissemination Positive (n = 19) Negative (n = 64)
1407 3p26.3 CNTN6 33 6 0.0009
503 3p24.3 UBE2E1 32 6 0.0009
2 2 94 q 3 1 . 1M A M L 3 4 4 5 < 0 . 0 0 0 1
Histologic type Diffuse (n = 42) Intestinal (n = 41)
1292 4q34.1 N.i. 17 53 0.0004
1393 5q33.2 TIMD4 15 48 0.0007
91 8p21.3 INTS10 0 24 0.0006
227 14q32.33 IGHV3-22 16 54 0.0001
1122 15q15.3 GANC, CAPN3 2 27 0.0003
1210 17q13.2 ATP2A3, ZZEF1 5 41 0.0001
N.I.; not identified
* χ2 test between two groups
Ratios (log2) that exceed >0.25 are considered DNA copy number gains, and ratios (log2) that exceed <-0.25 are considered to be DNA copy 
number losses.BMC Cancer 2008, 8:393 http://www.biomedcentral.com/1471-2407/8/393
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mini-array was reduced to one-tenth in comparison to the
original 1.4 K arrays that were used for the screening of the
DNA copy number changes in this study. Furthermore,
the number of spotted probes was much less in the
present mini-array than in the gene expression type arrays
such as the MammaPrint [25]. The mini-array developed
in this study allowing the estimation of the disease states
based on the DCNAs is unique. This is the first report of
the development of a BAC mini-array in order to estimate
the disease state of cancer. The diagnostic performance of
the mini-array was evaluated for a blinded set of 30 gastric
cancers independent of the training set of 83 cases.
The mini-array allows for the automatic differentiation
between the tumors with and those without a specific
characteristic. The overall accuracy for the blinded-sample
set was 66.7% (sensitivity; 0.95, and specificity; 0.0) for
node metastasis, 86.7% (sensitivity; 0.67 and specificity;
0.85) for liver metastasis, 86.7% (sensitivity; 0.67, and
specificity; 0.89) for peritoneal dissemination, and 96.7%
(sensitivity; 0.20, and specificity 1.0) for the depth of
tumor invasion. The mini-array provides a guideline for
the optimal treatment of each patient with gastric cancer.
Early cancers with a node-negative status are an indication
for EMR or ESD. Therefore, information concerning the
nodal state and the depth of tumor invasion is primarily
essential for the determination of the treatment methods
and can improve the quality of life for cancer patients. In
the differentiation between the early and advanced can-
cers, the diagnostic accuracy was as high as 96.7% (sensi-
tivity; 1.0, and specificity 0.67). However, the diagnostic
accuracy for nodal metastasis was not high; the false pos-
itive and false negative rates were 100% and 5%, respec-
tively. These findings indicate the validity of the practical
use of the mini-array to determine the optimal treatment
methods. However, the diagnostic accuracy, specificity
and sensitivity of the mini-array for the blinded samples
may not completely meet the requirement of surgeons at
present. The mini-array needs to be revised to improve the
diagnostic performance. The number of tumors examined
in this study was limited, and large-scale studies may iden-
tify the BAC clones with a stronger impact on the differen-
tiation between the tumors with and without specific
features.
Array CGH profiles of a case (J91) of gastric cancer in the dye-swap hybridization experiments for the mini-array Figure 3
Array CGH profiles of a case (J91) of gastric cancer in the dye-swap hybridization experiments for the mini-
array. The tumor DNA is labeled with Cy3 or Cy5, and the reference DNA is labeled with Cy5 or Cy3, respectively. Each 
data point along the ratio plot represents the normalized ratio of the individual clones linearly ordered from chromosome 1 to 
the Y chromosome. The intensity ratios above or below the threshold are depicted as green or red dots, respectively. Two 
profiles show a mirror state, though a slight discordance may be present between some dots. The copy number gain is unam-
biguous for the BAC clones in chromosome 8 in this case.
Table 4: Intratumoral genomic heterogeneity and diagnostic 
performance of the mini-array
Case No. Total
S39 B17 C22 I87 S50
Method 1
Node metastasis - + (1) - - + (2) 3/20
L i v e r  m e t a s t a s i s ----- 0 / 2 0
Peritoneal dissemination - - - - - 0/20
Early or advanced + (1) - - + (1) - 2/20
Histologic type* + (1) - - - + (2) 3/20
Method 2
Node metastasis - - - + (1) - 1/20
L i v e r  m e t a s t a s i s ----- 0 / 2 0
Peritoneal dissemination - - - - - 0/20
Histologic type* - - - + (1) - 1/20
The difference in diagnosis was rare between four samples from the 
same tumor. In particular, there were no BAC clones affecting the 
estimation of liver metastasis and peritoneal dissemination in all of the 
samples.
-; Absence of intratumoral genomic heterogeneity affecting diagnosis
+; Presence of intratumoral genomic heterogeneity affecting diagnosis 
(the number of clones different from others)
* Intestinal or diffuse typeBMC Cancer 2008, 8:393 http://www.biomedcentral.com/1471-2407/8/393
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CGH is technically applicable to biopsy specimens as well
as surgical ones, because a sufficient amount of genomic
DNA can be readily obtained from the biopsy specimens
[26]. Before the application of the mini-array to the
biopsy specimens, however, the issue of intratumoral het-
erogeneity must be investigated from the viewpoint of
diagnostic accuracy [27]. The effects of the intratumoral
heterogeneity on the diagnostic performance of the mini-
array were examined using four tissue specimens taken
from different parts of a cancer. The diagnosis by the mini-
array analysis was hardly different between the four tissue
specimens taken from a tumor. This indicates that biopsy
specimens as well as surgical ones can be applied to the
mini-array for the purpose of estimating the disease states
of gastric cancer. Therefore, the mini-array can be added to
a list of the laboratory examinations which can be used for
the diagnosis of gastric tumors and to also select the opti-
mal therapy.
Conclusion
We made the mini-array in order to estimate the degree of
node metastasis, liver metastasis, peritoneal dissemina-
tion, depth of mural invasion, and the histologic type of
gastric adenocarcinoma with a high degree of accuracy.
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